MedTrace Logo

A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.

NCT07648472 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-06-15

No results posted yet for this study

Summary

This is an open-label, single-arm, dose escalation clinical study to evaluate the safety and preliminary efficacy of OVV-01 Injection in patients with advanced solid tumors, following both intravenous (iv.) and intratumoral (it.) injections. This study consists of two parts: Part 1 is a dose escalation study of iv. administration; Part 2 is a dose escalation study of iv. and it. administration.

Conditions

Interventions

DRUG

OVV-01 Injection

Dose group 1: 6×10 10 PFU/subject; Dose group 2: 6×10 11 PFU/subject;

DRUG

OVV-01 Injection

Dose group 1: 6×10 10 PFU/mL(it.) + 6×10 10 PFU/subject (iv.); Dose group 2: 6×10 10 PFU/mL(it.) +6×10 11 PFU/subject (iv.);

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Joint Biosciences Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2027-04-20
Completion
2027-04-20
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07648472 on ClinicalTrials.gov